Home Air Quality Impact for Adults With Asthma

July 28, 2025 updated by: University of Kansas Medical Center

The Changing COVID-19 Landscape: A Feasibility Study to Capture Momentary Residential Environmental Exposures and Asthma Symptoms in Adults

The purposes of this study are to determine the practicality of using home indoor air quality monitoring and a smartphone app to identify home air quality changes and how these changes affect adults with asthma.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The aims of this feasibility study are: 1) determine the feasibility and usability of: (a) ecological momentary assessment (EMA) to assess self-report residential environmental exposures and asthma symptoms, (b) home monitoring of objective environmental exposures (total volatile organic compounds [VOCs], particulates [PM2.5]), and lung function (home spirometry); 2a) assess the frequency and degree of residential environmental exposures (e.g., disinfectants/cleaners, second-hand smoke) via (a) self-reported data, and (b) home monitoring objective measures, 2b) assess the level of asthma control as indicated by self-reported asthma symptoms and lung function; and 3) explore associations of self-reported and objective measures of residential environmental exposures with self-reported and objective measures of asthma control. Participants will receive an indoor air quality monitor and a home spirometer to measure VOCs, PM2.5, and forced expiratory volume percent predicted, respectively. EMA will be collected using a personal smartphone and EMA software platform. Participants' will be sent scheduled and random EMA notifications to assess asthma symptoms, environmental exposures, lung function, and mitigation strategies. After the 14-day data collection period, participants will respond to survey items related acceptability, appropriateness, and feasibility.

Study Type

Observational

Enrollment (Actual)

64

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Kansas
      • Kansas City, Kansas, United States, 66160
        • Barbara J Polivka

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Adults with asthma living in the US

Description

Inclusion Criteria:

  • Adults who previously participated in the online Global Covid-19 and Asthma Study, indicated willingness to be contacted for future research, and reported high use of disinfectant/cleaning products since COVID-19 (≥5 per week).
  • Current Asthma Control Test (ACT) ≤19
  • Own a smartphone
  • Have a Wi-Fi/wireless internet connection in their home.

Exclusion Criteria:

  • Non-US residents
  • Non-English speaking

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Episodes Per Day
Time Frame: Measured daily for 14 days
Number of episodes per day that the residential VOCs exceeded 333 ppb and/or PM2.5 exceeded 15 mg/m3, as measured by the Awair home air quality monitor
Measured daily for 14 days
Home Spirometry Completed
Time Frame: Assessed daily for 14 days
Number of participants completing daily home spirometry over 14 days.
Assessed daily for 14 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Integration of Study Components
Time Frame: 14 days
Participants were asked one survey item to assess if the various components of the study were well integrated. Response options ranged from 0=Strongly disagree to 4=Strongly agree. The score was multiplied by 25; scores could range from 0-100. A higher score indicated that the study components were well integrated.
14 days
Ecological Momentary Assessment (EMA) Surveys
Time Frame: 14 days
Number of participants completing air quality triggered EMA surveys
14 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Kansas Medical Center

Collaborators

National Institute of Environmental Health Sciences (NIEHS)

Investigators

  • Principal Investigator: Barbara Polivka, PhD, Select

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 30, 2022

Primary Completion (Actual)

February 28, 2024

Study Completion (Actual)

February 28, 2024

Study Registration Dates

First Submitted

January 10, 2022

First Submitted That Met QC Criteria

January 31, 2022

First Posted (Actual)

February 4, 2022

Study Record Updates

Last Update Posted (Actual)

July 29, 2025

Last Update Submitted That Met QC Criteria

July 28, 2025

Last Verified

July 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • STUDY00145830
  • R21ES033118 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

To maximize the utility of this research, and in the interests of allowing other researchers and the public to benefit from it, the investigators will make the entire protocol and deidentified dataset available to researchers.

IPD Sharing Time Frame

Up to 24 months after the publication of the main study findings.

IPD Sharing Access Criteria

Requests for IPD will be reviewed by the MPIs once a formal email request is submitted for research addressable aims/questions/hypotheses. Once the request has been approved by the MPIs and IRB approval is obtained, only deidentified data relevant to the research questions will be shared for secondary analyses deemed appropriate by the MPIs.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Asthma

Clinical Trials on Home Air Quality

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe